SubHero Banner

Tafinlar® (dabrafenib) and Mekinist® (trametinib) – New indication

April 30, 2018 - Novartis announced the FDA approval of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

Download PDF